Lipella Pharmaceuticals Inc.
LIPO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 19.3% | 144.2% | -29% | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | -573.7% | -575.9% | -1,283.4% | -461.7% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -934.7% | -1,024.5% | -1,405.4% | -716.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -935.2% | -1,027.3% | -1,410.6% | -719.3% |
| EPS Diluted | -4.79 | -6.16 | -5.12 | -4.38 |
| % Growth | 22.2% | -20.3% | -16.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |